● Recruiting

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Condition: Relapsed Refractory Multiple Myeloma · Sponsor: AstraZeneca

PhasePhase 3

Planned participants508

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (138)

Research Site	Gilbert, Arizona, United States	Not Yet Recruiting
Research Site	Phoenix, Arizona, United States	Withdrawn
Research Site	Tucson, Arizona, United States	Not Yet Recruiting
Research Site	La Jolla, California, United States	Withdrawn
Research Site	Sacramento, California, United States	Not Yet Recruiting
Research Site	Santa Monica, California, United States	Not Yet Recruiting
Research Site	Denver, Colorado, United States	Not Yet Recruiting
Research Site	New Haven, Connecticut, United States	Recruiting
Research Site	Washington D.C., District of Columbia, United States	Not Yet Recruiting
Research Site	Coral Gables, Florida, United States	Not Yet Recruiting
Research Site	Tampa, Florida, United States	Not Yet Recruiting
Research Site	Atlanta, Georgia, United States	Not Yet Recruiting

+ 126 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07391657